Correlation between ERCC1, XRCC1 expression and platinum in non-small cell lung cancer with malignant pleura effusion
KONG Yan?
ZUO Jing
LIU Liang
LIU Rongfeng
JIANG Da
Abstract：Objective To investigate the relationship between ERCC1, XRCC1expression level in malignant pleural effusion of non-small cell lung cancer ( NSCLC) and the efficacy of platinum based chemotherapy and prognosis. Methods From 2012 March to 2014 March, 82 cases receiving platinum drug regimens for the treatment of malignant pleural effusion of advanced NSCLC were enrolled, using flow cytometry to test ERCC1, XRCC1 protein expression level in pleural effusion, using Kaplan-Meier survival curve analysis to compare different ERCC1 and XRCC1 expression level in patients with median survival (OS) and stage to disease free progression (PFS). Results The positive rate of ERCC1 was 41. 5% (34/82), the positive rate of XRCC1 was 34. 1% (28/82). ERCC1 negative expression with platinum based chemotherapy was more effec-tive than the positive expression of persons, but no significant difference between the two regime (χ2 =0. 63, P =0. 43);XRCC1 negative expression contain platinum based chemotherapy was more effective than the positive expression, no signifi-cant difference were found between the two regime (χ2 =0. 01, P =0. 93). The negative expression of ERCC1 and XRCC1 patients’ OS was significantly longer than the positive expression patients (χ2 =5. 91, P <0. 05);PFS also was significantly longer than that of the positive expression patients (χ2 =15. 31, P <0. 05). Conclusion Pleural effusion’s tumor cells of ERCC1, XRCC1 expression is related to the prognosis of late stage small cell lung cancer, and the relationship with platinum agent chemotherapy remains unclear.
Keywords：ERCC1XRCC1Non-small cell lung cancerPleural effusionPlatinum
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 771-774 )